The global cardiac marker testing market is estimated to grow at a CAGR of 8.8% from 2016 to 2021 to reach USD 3.50 billion by 2021.
Factors such as growing incidences of cardiovascular diseases, the rapidly increasing geriatric population, growing funding from public-private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers are fueling the growth of the cardiac marker testing market. On the other hand, technical problems related to sample collection and storage and issues related to regulatory and reimbursement systems are the key factors limiting the growth of the global cardiac marker testing market.
Geographically, North America commands the largest share of the global cardiac marker testing market in 2016, followed by Europe. The cardiac marker testing market in North America is primarily driven by the increasing incidence of cardiovascular diseases, growing public-private investments, NIH support towards the development of novel cardiac biomarkers, and rising geriatric population.
The cardiac marker testing market is highly competitive owing to the presence of a number of large and small firms. With improving industry standards, the global market has been witnessing several product innovations. New product launches was the key growth strategy adopted by market players to strengthen their market positions.
Guangzhou Wondfo Biotech Co., Ltd.
LSI Medience Corporation
Ortho Clinical Diagnostics
Randox Laboratories Ltd.
Roche Diagnostics Limited
Key Topics Covered:
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Industry Insights
7 Cardiac Marker Testing Market, By Type
8 Cardiac Marker Testing Market, By Product
9 Cardiac Marker Testing Market, By Disease
10 Cardiac Marker Testing Market, By Type of Testing